Dr. Gomella on Sequencing Prostate Cancer Therapies

[Anonymous]

[good video , ie, provenge first:]

http://www.onclive.com/onclive-tv/Dr-Gomella-on-Sequencing-Prostate-Cancer-Therapies

Leonard G. Gomella, MD

Published Online: Monday, March 25, 2013

Leonard G. Gomella, MD, professor and chair of the Department of Urology at the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC).

Gomella believes that researchers will be studying optimal therapeutic sequences in mCRPC for 3 to 5 years. Several agents have been recently approved and many more are still awaiting approval. At this point, Gomella adds, data are not available to support an optimal sequence, with one caveat, sipuleucel-T (Provenge).

Overall, Gomella notes, a consensus is emerging that sipuleucel-T should be administered earlier in asymptomatic patients who have recently been diagnosed with metastatic disease. Outside of sipuleucel-T, Gomella notes, researchers are still examining the optimal sequence for other recently approved agents, including cabazitaxel (Jevtana), abiraterone acetate (Zytiga), and enzalutamide (Xtandi).

 

[Anonymous]

For you mental midgets out there who don't know Len Gomella, he was one of our initial 50 accounts at launch but he refused to use Provenge. Gomella, like so many thought leaders, makes his money by getting into the pockets of pharma companies and blowing sweet nothings in their ear.

 

[Anonymous]

Speaking of mental midgets - you are a fraud and serial liar. Dr. Gomez and his medical associates are heavy prescribers of provenge and you should be in prison or a mental institution.

 

[Anonymous]

Did you say, Gomez? The only Gomez I know is from Addams family, a-hole.

 

[Anonymous]

I know for a fact that Dr. Gomella and his medical associates are heavy prescribers of provenge. Provenge is steadily gaining acceptance in the medical community.